首頁 > 市場調查報告書 > 製藥

癌症婦科治療

市場調查報告書

商品編碼

1820146

脂質體阿黴素市場報告（按產品（Doxil/Caelyx、Lipodox、Myocet 等）、應用（白血病、骨肉瘤、乳腺癌、子宮內膜癌、腎癌、多發性骨髓瘤、卡波西肉瘤等）和地區）2025-2033

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2025-2033

出版日期: 2025年09月01日 | 出版商:

IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024 年全球脂質體阿黴素市場規模達 13.4 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 20.6 億美元，2025-2033 年期間的成長率 (CAGR) 為 4.9%。

脂質體阿黴素是一種化療藥物，用於治療各種自體免疫疾病以及肝癌、乳癌、子宮內膜癌、胃癌和腎癌。它的作用機轉是阻止或減緩體內癌細胞的生長。該藥物被聚乙二醇化脂質體包裹，並透過靜脈注射給藥。阿黴素藥物能夠阻斷癌細胞分裂和生長所需的酶，脂質體則確保藥物在血液中停留更長時間，從而到達癌細胞，增強療效。該藥物的劑量取決於患者的體重、身高和整體健康狀況。與傳統藥物相比，脂質體阿黴素的毒性、骨髓抑制、脫髮和噁心症狀均較小。

脂質體阿黴素市場趨勢：

在全球範圍內，骨肉瘤、多發性骨髓瘤、卵巢癌和自體免疫缺陷症候群（愛滋病）相關的卡波西氏肉瘤等慢性疾病的發生率不斷上升，是推動市場成長的關鍵因素之一。這可以歸因於大多數勞動人口久坐不動的生活方式和繁忙的工作日程，這反過來又顯著增加了這些疾病的發病率，並對脂質體阿黴素藥物的需求產生了積極影響。此外，大眾對現有癌症治療替代方案的認知不斷提高，也推動了市場的成長。諸如典型奈米藥物的開發和化療藥物的改進等各種進步，也起到了促進生長的作用。這些創新有助於藥物在體內實現定點輸送和控制釋放。其他因素，包括醫療保健基礎設施的顯著改善（尤其是發展中經濟體），以及腫瘤學領域的廣泛研究和開發 (R&D) 活動，預計將推動市場成長。

本報告回答的關鍵問題：

到目前為止，全球脂質體阿黴素市場表現如何，未來幾年將如何表現？
COVID-19 對全球脂質體阿黴素市場有何影響？
主要的區域市場有哪些？
根據產品，市場是如何分類的？
根據應用，市場是如何分類的？
該產業的價值鏈分為哪些階段？
該行業的主要促進因素和挑戰是什麼？
全球脂質體阿黴素市場的結構是怎麼樣的？主要參與者是誰？
產業競爭程度如何？

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

Liposomal Doxorubicin Market Trends:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Product:

Doxil/Caelyx
Lipodox
Myocet
Others

Breakup by Application:

Leukemia
Bone Sarcoma
Breast Cancer
Endometrial Cancer
Kidney Cancer
Multiple Myeloma
Kaposi Sarcoma
Others

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

Key Questions Answered in This Report:

How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global liposomal doxorubicin market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global liposomal doxorubicin market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Liposomal Doxorubicin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Doxil/Caelyx
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Lipodox
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Myocet
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Application

7.1 Leukemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Bone Sarcoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Breast Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Endometrial Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Kidney Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Multiple Myeloma
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Kaposi Sarcoma
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia-Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Baxter International Inc.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Cipla Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Johnson & Johnson
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Merck KGaA
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
  - 13.3.5.4 SWOT Analysis
- 13.3.6 Sun Pharmaceutical Industries Ltd
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 TTY Biopharm Company Limited
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
- 13.3.9 Zydus Cadila
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio

簡介目錄圖表

List of Figures

Figure 1: Global: Liposomal Doxorubicin Market: Major Drivers and Challenges
Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2024
Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2024
Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2024
Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million USD), 2019 & 2024
Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2024
Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Liposomal Doxorubicin Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Liposomal Doxorubicin Market Forecast: Breakup by Product (in Million USD), 2025-2033
Table 3: Global: Liposomal Doxorubicin Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 4: Global: Liposomal Doxorubicin Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 5: Global: Liposomal Doxorubicin Market: Competitive Structure
Table 6: Global: Liposomal Doxorubicin Market: Key Players

02-2729-4219

+886-2-2729-4219